Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies.
The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medical technology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest.
Thomas, McNerney & Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.
|AxioMed Spine||1/13||Series D||$3.6M||5|
|Auspex Pharmaceuticals||11/12||Series D||$25M||4|
|Torax Medical||9/12||Series D||$30M||5|
|Tioga Pharmaceuticals||4/12||Series B||$10M||2|
|SG Biofuels||1/12||Series B||$17M||4|
|CAS Medical Systems||6/11||Venture Round||$15M||1|
|AxioMed Spine||10/10||Series D||$15M||7|
|Auspex Pharmaceuticals||10/10||Series C||$12M||3|
|Celator Pharmaceuticals||9/10||Series D||$20M||7|
|NeuroTherapeutics Pharma||5/10||Series B||$43M||4|
|Altair Therapeutics||2/10||Series B||$17M||4|
|Intuity Medical||1/10||Series D||$64M||6|
|Quinnova Pharmaceuticals||11/09||Series B||$17.4M||3|
|Virdante Pharmaceuticals||11/09||Series A||$30M||6|
|Galil Medical||12/06||Venture Round||$52M||3|
|Solstice Neurosciences||11/06||Series B||$85M||5|
|Solstice Neurosciences||7/05||Venture Round||$8M||4|
|Torax Medical||6/05||Series B||$10M||3|